|Mr. Dilip Shantilal Shanghvi||N/A||N/A||62|
|Mr. Chetan Rajpara||1.72M||N/A||N/A|
|Mr. Debashis Dey||2.43M||N/A||N/A|
|Mr. Anil Raghavan||N/A||N/A||N/A|
|Dr. Subhas Bhowmick||N/A||N/A||61|
Sun Pharma Advanced Research Company Limited operates as a pharma research and drug discovery company in India and internationally. It develops new chemical entities and products based on its proprietary novel drug delivery systems. The companys core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as developing abuse deterrent formulations. It offers Levetiracetam ER for epilepsy. The company is also developing Latanoprost BAK free eye drops for glaucoma; Baclofen gastric retention systems for spasticity; salmeterol-fluticasone DPI for asthma/COPD; paclitaxel injection concentrates for nanodispersion for the treatment of cancer; SUN-K706 and SUN-K095 for chronic myelogenous leukemia; and Brimonidine OD for glaucoma. In addition, it is developing SDN-021 and Tizanidine ER for pain; SUN-597 Topical for atopic dermatitis; minocycline topical for acne; and octreotide LAR for acromegaly. The company was incorporated in 2006 and is based in Vadodara, India. As of March 30, 2017, Sun Pharma Advanced Research Company Limited operates as a subsidiary of Shanghvi Finance Pvt. Ltd.
Sun Pharma Advanced Research Company Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.